GlassScriptPhysician profile
Kevin Dinsmore
NPI 1447625785
$1,785.48
in general payments reported to CMS, 2019-2025
21 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.33 · 2022: $50.94 · 2023: $208 · 2024: $285 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,688.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $293.33 | 2022-2025 | Belbuca |
| Ani Pharmaceuticals, INC. | $256.84 | 2025 | Purified Cortrophin Gel |
| Scilex Pharmaceuticals INC. | $231.96 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $209.43 | 2024-2025 | Relistor |
| Valinor Pharma, LLC | $192.50 | 2024-2025 | Movantik |
| Si-Bone, INC. | $72.79 | 2025 | |
| Endo USA, INC. | $68.93 | 2024 | Xiaflex |
| Azurity Pharmaceuticals, INC. | $57.22 | 2025 | Horizant |
| Relievant Medsystems, INC. | $49.28 | 2023 | Intracept |
| Almatica Pharma LLC | $46.33 | 2021 | |
| Averitas Pharma INC. | $46.00 | 2023 | Qutenza |
| Ibsa Pharma INC. | $45.00 | 2023-2024 | Tirosint, Licart, Licart |
| Depuy Synthes Sales INC. | $40.91 | 2022-2024 | Monovisc, Orthovisc |
| Pacira Pharmaceuticals Incorporated | $34.95 | 2023 | Iovera, Zilretta |
| Endo Pharmaceuticals INC. | $33.53 | 2023-2024 | Xiaflex |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $20.98 | 2025 | Symbravo |
| Convatec INC. | $20.06 | 2023 | |
| Pfizer INC. | $19.61 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $16.57 | 2023 | Seglentis |
| Bioventus LLC | $15.75 | 2022 | |
| Abbvie INC. | $13.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Dinsmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.